On March 2, 2021 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) reported that according to the analysis of the preliminary results during the ongoing year end closing process, MorphoSys’ outlook has been exceeded (Press release, MorphoSys, MAR 2, 2021, View Source [SID1234575983]). Group revenues for 2020 are expected to amount to € 327.7 million and therefore slightly above the upper end of the guidance range from € 317 to 327 million. Group revenues include € 18.5 million (USD 22.0 million) revenues from product sales of Monjuvi as well as € 42.5 million for royalties on net sales of Tremfya. EBIT (Earnings before Interests and Taxes) for 2020 is expected to be € 27.4 million, and therefore significantly above the upper end of the guidance range of € 10 to 20 million. Expenses for research and development are expected to amount to € 141.4 million and therefore slightly above the guided range of € 130 to 140 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All figures are preliminary. Full results will be published as planned on March 15, 2021.